Foundayo (orforglipron)

What this page used to say

• 2026-09-13 — What Foundayo's label says to do when side effects do not settle. Was: A tablet rather than an injection, and the same class effects: the route changes, the stomach does not. Nausea, diarrhea, vomiting and constipation are the reason most people stop. They are worst in the first days after each dose increase and usually settle; a schedule held longer at one step is the standard answer, and it is a conversation with the prescriber rather than a reason to quit unannounced. Now: A tablet rather than an injection, and the same class effects: the route changes, the stomach does not. In the two trials 8% stopped because of side effects, against 3% on placebo, 5% of them because of gastrointestinal ones. Nausea, vomiting and diarrhea were more common during dose escalation and decreased over time. Above 5.5 mg every step is optional, taken on response and tolerability, so the pace is a conversation with the prescriber rather than a reason to quit unannounced.
• 2026-09-12 — Foundayo's price once titrated. Was: Lilly sells it direct at $149 a month to start and $299 once titrated. The pill removes the injection, not the escalation: the top dose is at least 150 days away. Now: LillyDirect self-pay reads $149 a month at 0.8 mg and 2.5 mg, $199 at 5.5 mg, the lowest maintenance dose, and $299 at 9 mg and above. The 2.5 mg and 5.5 mg prices are reductions that end 31 December 2026, and the $299 at 14.5 mg and 17.2 mg holds only with a refill within 45 days; miss it and those two doses are $349. The pill removes the injection, not the escalation: the top dose is at least 150 days away.
• 2026-09-11 — The Foundayo price note. Was: $149 at the 0.8 mg starting dose, $199 at the next step, $299 at higher doses (read 19 August). Now: $149 at 0.8 mg and 2.5 mg, $199 at 5.5 mg, $299 from 9 mg (read 11 September).
• 2026-09-11 — A point in its favor that no longer stood. Was: $149/mo at the entry dose through LillyDirect is the lowest price for any branded FDA-approved weight-loss drug. Now: $149 a month at the entry dose through LillyDirect — the lowest self-pay price for a branded GLP-1 on this site, matched only by the Wegovy pill's first month.
• 2026-09-11 — The missed-dose rule on the dosage page. Was: the label says to restart escalation at a lower dose. Now: the label says to restart escalation at the 0.8 mg starting dose.
• 2026-09-11 — Foundayo's common side effects, read again from its label. Was: Six: nausea, diarrhea, vomiting, constipation, indigestion, abdominal pain. Now: Thirteen, in the label's order: nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, bloating, fatigue, burping, reflux, flatulence, hair loss.
• 2026-09-05 — Changed the trial figure to the intention-to-treat result on the FDA label. Was: ATTAIN-1, phase 3: mean 14.7% body weight lost at the highest dose over 72 weeks. Now: 11.1% — ATTAIN-1, Trial 1 on the label, 72 weeks: 11.1% mean weight loss at 17.2 mg against 2.1% on placebo, intention-to-treat.
• 2026-09-05 — Corrected the maintenance dose, the week it is reached, and the missed-dose rule on the dosage page. Was: Maintenance dose: 9 mg, 14.5 mg or 17.2 mg daily, reached at the earliest in week 13. Missed dose: 'One tablet a day, swallowed whole, with or without food. Never two in a day.' Now: Maintenance dose: 5.5 mg, 9 mg, 14.5 mg or 17.2 mg daily, reached at the earliest in week 9, with a note on the 5.5 mg step that it is the first dose the label does not require you to leave. Missed dose: take it as soon as possible, do not double up the next one, and after 7 or more consecutive missed doses restart escalation at a lower dose.
• 2026-09-05 — Rewrote the boxed-warning summary on the side-effects page to say what the label says about rodents. Was: In rodents this molecule caused thyroid C-cell tumors at human-relevant doses. Now: The label carries the GLP-1 class boxed warning and says why it applies here: other GLP-1 receptor agonists that are active in rats and mice caused thyroid C-cell tumors; orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents; because it is active at the human GLP-1 receptor, the human relevance has not been determined.
• 2026-09-05 — Rebuilt the serious reactions as the label's section 5, in the label's order. Was: Five items: acute pancreatitis, severe gastrointestinal reactions, acute kidney injury, hypoglycemia, hypersensitivity reactions. Now: Eight, in label order: acute pancreatitis (5.2), severe gastrointestinal reactions (5.3), acute kidney injury (5.4), hypoglycemia (5.5), hypersensitivity reactions (5.6), diabetic retinopathy complications (5.7), acute gallbladder disease (5.8), pulmonary aspiration under anesthesia (5.9).
• 2026-09-05 — The self-pay ladder, and the condition on the $299. Was: $149 at the 0.8 mg starting dose, $299 at 14.5 mg and 17.2 mg. The $299 holds only with a refill inside 45 days; otherwise those doses are $349. Now: $149 at 0.8 mg and 2.5 mg, $199 at 5.5 mg, $299 at 9 mg, 14.5 mg and 17.2 mg. The 2.5 mg and 5.5 mg prices are temporarily reduced through 31 December 2026, and the $299 needs a refill inside 45 days.
• 2026-09-05 — Re-read Lilly's Foundayo price for each dose. Was: 0.8 mg $149, 2.5 mg $199, then $299 from 5.5 mg with a $349 lapsed price on every fill from 5.5 mg: $3,338 in year one, $3,838 if the refill window was ever missed. Now: 0.8 mg $149, 2.5 mg $149, 5.5 mg $199, 9 mg $299, then $299 at 14.5 mg and 17.2 mg, one 30-tablet bottle a month: $3,188 in year one. Only the two top doses carry the 45-day refill condition, so the year after a missed window is $3,588.

Every correction on this site, dated →